Should Calumet’s (CLMT) Analyst Downgrade and Weak Earnings Prompt a Reassessment by Investors?

Simply Wall St.

Oct 12

Earlier this week, Zacks Research downgraded Calumet (NASDAQ:CLMT) to a strong sell, following quarterly earnings that came in below analysts’ consensus estimates. This shift in analyst sentiment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2574415656"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574415656\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574415656?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/1033000-choice2-main-header/1585186657557","is_english":true,"pubTime":"2025-10-12 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574415656","market":"us","top_or_hot":-1,"title":"Should Calumet’s (CLMT) Analyst Downgrade and Weak Earnings Prompt a Reassessment by Investors?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this week, Zacks Research downgraded Calumet (NASDAQ:CLMT) to a strong sell, following quarterly earnings that came in below analysts’ consensus estimates. This shift in analyst sentiment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/energy/nasdaq-clmt/calumet/news/should-calumets-clmt-analyst-downgrade-and-weak-earnings-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Calumet’s (CLMT) Analyst Downgrade and Weak Earnings Prompt a Reassessment by Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Calumet’s (CLMT) Analyst Downgrade and Weak Earnings Prompt a Reassessment by Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-12 18:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/energy/nasdaq-clmt/calumet/news/should-calumets-clmt-analyst-downgrade-and-weak-earnings-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, Zacks Research downgraded Calumet (NASDAQ:CLMT) to a strong sell, following quarterly earnings that came in below analysts’ consensus estimates. This shift in analyst sentiment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/energy/nasdaq-clmt/calumet/news/should-calumets-clmt-analyst-downgrade-and-weak-earnings-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/energy/nasdaq-clmt/calumet/news/should-calumets-clmt-analyst-downgrade-and-weak-earnings-pro","article_id":"2574415656","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/1033000-choice2-main-header/1585186657557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/energy/nasdaq-clmt/calumet/news/should-calumets-clmt-analyst-downgrade-and-weak-earnings-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2574415656","pubTimestamp":1760264278,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this week, Zacks Research downgraded Calumet (NASDAQ:CLMT) to a strong sell, following quarterly earnings that came in below analysts’ consensus estimates.\nThis shift in analyst sentiment highlights growing uncertainty around the company’s near-term performance and reflects heightened caution regarding its earnings potential.\nWe’ll assess how this analyst downgrade and weaker earnings performance affect Calumet’s investment narrative and outlook for margin resilience.\nRare earth...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","CLMT":"卡路美"},"translate_title":"Calumet(CLMT)分析师评级下调和盈利疲软是否会促使投资者重新评估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLMT":1.5,"ISBC":1.5},"content_text":"Earlier this week, Zacks Research downgraded Calumet (NASDAQ:CLMT) to a strong sell, following quarterly earnings that came in below analysts’ consensus estimates. This shift in analyst sentiment highlights growing uncertainty around the company’s near-term performance and reflects heightened caution regarding its earnings potential. We’ll assess how this analyst downgrade and weaker earnings performance affect Calumet’s investment narrative and outlook for margin resilience. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.AdvertisementCalumet Investment Narrative Recap To be a shareholder in Calumet, you generally need to believe in a rebound in renewables profitability, resilient margins for specialty products, and successful debt reduction, anchored by execution of major projects like MaxSAF 150. Zacks Research’s downgrade to strong sell, coming after weaker-than-expected earnings, raises concerns about Calumet’s ability to deliver near-term margin improvements and amplifies the biggest risk: pressure on margins if regulatory support for renewables falters. While this shift is serious, the core long-term catalysts, like the MaxSAF 150 project, still underpin the investment case unless earnings weakness persists or intensifies.\n\nOne recent announcement with strong relevance is the Q2 2025 earnings release, where Calumet reported a net loss of US$147.9 million despite ongoing cost-reduction efforts. This earnings shortfall is a key factor in the shift in analyst sentiment and highlights operational and regulatory headwinds that may directly impact Calumet’s progress on high-profile initiatives such as expanding renewable fuel capacity.\n\nHowever, investors should be aware that for all the focus on future growth, mounting debt and cash flow constraints remain a critical source of risk if...\n Read the full narrative on Calumet (it's free!)Calumet's narrative projects $5.1 billion revenue and $40.3 million earnings by 2028. This requires 8.0% yearly revenue growth and a $493.1 million increase in earnings from -$452.8 million.Uncover how Calumet's forecasts yield a $19.05 fair value, a 8% upside to its current price.Exploring Other PerspectivesCLMT Earnings & Revenue Growth as at Oct 2025  Simply Wall St Community fair value estimates for Calumet range widely from US$19.05 to US$52.30, based on three distinct member analyses. Persistent margin risk tied to evolving regulatory support is a factor that may influence these diverse outlooks, making it important to consider multiple viewpoints before forming your own.\nExplore 3 other fair value estimates on Calumet - why the stock might be worth just $19.05!Build Your Own Calumet NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Calumet research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free Calumet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Calumet's overall financial health at a glance.Searching For A Fresh Perspective?Our top stock finds are flying under the radar-for now. Get in early:Find companies with promising cash flow potential yet trading below their fair value.AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}